

Certificate of Approval of a Prospectus pursuant to Prospectus Regulation (EU) 2017/1129 of the European Parliament and of the Council Certificate Reference - 325379**To:** Financial Services and Markets Authority, Belgium**From:** Financial Conduct Authority, United Kingdom

We hereby certify that the Prospectus detailed below has been drawn up pursuant to Prospectus Regulation (EU) 2017/1129 of the European Parliament and of the Council and was approved by us on 24th March 2020.

Name of Issuer(s): Acacia Pharma Group plc**LEI:** 213800SLDKXWKT6E3381**Registered Office(s):** England and Wales**Type of Securities (if applicable):** Issues of New Ordinary Shares in connection with the Byfavo™ Acquisition**National Prospectus Identifier:** PRO05187**(references to the annexes of Regulation used):** Annex 3, 12 & 20**Name of the Guarantor(s) (if any):** N/A

We have authorised, in accordance with Article 18 of Prospectus Regulation (EU) 2017/1129, the omission of the information required on the following grounds: **No omission**

FCA Stamp:

For and on behalf of the Financial Conduct Authority

Date: 24th March 2020

Attachments: Prospectus